Nymalize - (6 mg/mL ; Oral Solution)

Generic Name	Nimodipine	Innovator	Arbor Pharmaceuticals
Dosage	6 mg/mL ; Oral Solution	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	NYMALIZE is a dihydropyridine calcium channel blocker indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V).
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** / ***	**** **, ****	*******	********* ********	******* *** **** *** *** ****
******	** / **	*** **, ****	*******	********* ********	***** ***-**** ***********

Chronology Of Events